Pharmacists in Killeen, Texas


61 Pharmacists found in Killeen
female pharmacist

Stacy Post, RPH


Pharmacist
1400 Lowes Blvd, Killeen, TX 76542
254-526-4433     254-526-4325

female pharmacist

Stephanie Garcia, PHARM D


Pharmacist
1000 E Central Texas Expy, Killeen, TX 76541
254-526-8809    

male pharmacist

Stephen Michael Igleheart, PHARMD


Pharmacist
3300 W Stan Schlueter Loop, Killeen, TX 76549
254-526-4566     254-526-4562



female pharmacist

Dr. Tammana Patel, PHARMD


Pharmacist
2511 Trimmier Rd, Killeen, TX 76542
254-634-2370    

male pharmacist

Tariq Ahmad


Pharmacist
3300 W Stan Schlueter Loop, Killeen, TX 76549
254-526-4566    

male pharmacist

Dr. The Ke Ha, PHARMD


Pharmacist
4201 Flamingo Dr, Killeen, TX 76549
254-383-4348    

male pharmacist

Mr. Thien D Nguyen, PHARMD


Pharmacist
1101 S Fort Hood St, Killeen, TX 76541
254-526-2444    

female pharmacist

Thucvu Thanh Nguyen, RPH


Pharmacist
1000 E Central Texas Expy, Killeen, TX 76541
254-526-4258     254-526-8809

female pharmacist

Tia Mecole Scott, PHARM D


Pharmacist
1000 E Central Texas Expy, Killeen, TX 76541
254-526-4258    

male pharmacist

Toan D Nguyen, PHARMD


Pharmacist
1000 E Central Texas Expy, Killeen, TX 76541
254-526-4258    

male pharmacist

Tyler Mohr, PHARM. D.


Pharmacist
2201 S Clear Creek Rd, Pharmacy Department-507, Killeen, TX 76549
254-519-8267    

male pharmacist

Tyler Ken Hirokawa


Pharmacist
1400 Lowes Blvd, Killeen, TX 76542
254-526-4433    

female pharmacist

Zairy Josel Sanchez Lozano


Pharmacist
2511 Trimmier Rd Ste 100, Killeen, TX 76542
254-634-2370    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.